http://www.ny1.com/content/lifestyle...son-s-disease/

Austrian biotech company AFFiRis AG announced positive results of a phase one safety study for a vaccine that could slow or even stop the progression of Parkinson's.

This drug looks very promising, but they state that it is 6-8 years before it would be available, if all goes well in trial. I am wondering, if it passes muster in phase 3 trial, whether it might be fast-tracked.... I'll keep my fingers crossed. Maybe there are some natural analogs that work similarly that might reduce alpha synuclein in the brain that may be available now.

Blackfeather, you may want to check a couple of posts from a few weeks ago when we discussed this study after the news came out. The only location for the new AffiRis study will be in Austria. However, at their webinar/conference two weeks ago (sorry, I don't have the link handy but you'll find it in the thread) they did imply they would consider US locations for the next Phase if the trials move forward. That would probably be sometime the end of next year or early 2016 (a wait, but not nearly 6 - 8 years). So, you can consider joining a future study and hope you get the drug rather than placebo.

Alternatively, you can also consider the currently recruiting study for Prothena ( http://ir.prothena.com/releasedetail...leaseID=863495 ). They are also conducting research on an a-syn antibody. Although it's only a phase 1 study, some researchers I've spoken with are more impressed with their drug and methodology than AffiRis. As the trial has just begun, it will probably go on for at least a year, so you have some time before you would need to join. In addition, even if you were to wait for a possible phase 2, it will certainly be less than 6 years. In most of the trials, your odds of getting the drug as opposed to a placebo will probably be 2 -1 or 3 -1.

I, along with several other members on this board, have had discussions with the trial teams about Prothena's drug PRX002. We will watch it closely, see how the trial proceeds, and make some decisions later.

I suggest considering this approach for two reasons. First, we need volunteers for PD trials worldwide if we ever want to see drugs go through the long research process prior to filing an NDA and receiving approval. Second, if you are going to take a shot at a neuroprotective antibody, I would think you would want to do so with one that has some degree of real science behind it, positive pre-clinical research, and positive phase 1 safety studies. As opposed to a natural analog, if one exists, that no one has the slightest idea about how it would function. These are monoclonal antibodies that may have effects on the body and other proteins that we are not aware of at this time.

Gary

While we are waiting... and waiting...and waiting, there is

Baikal (Chinese) Skullcap. http://onlinelibrary.wiley.com/doi/1...201000604/full. Swanson has it,

Curcumin http://pubs.acs.org/doi/abs/10.1021/cn3001203
I use www.longvida.com which is highly bioavailable.

It works well with beta cyclodextrin but I don't know where to find that. http://pubs.acs.org/doi/abs/10.1021/bi500642f

and as previously posted by Conductor71. http://www.ncbi.nlm.nih.gov/pmc/arti...4/?tool=pubmed, serotonin is important. That might be why Dr. Hinz emphasizes balancing serotonin and why he says his protocol stops progression (that and addressing the glutathione deficiency.)

Thanks guys for all the great info provided. Seems curcumin has shown effectiveness in reducing alpha-synuclein in some research. http://www.biomedcentral.com/1471-2202/11/57. Can't hurt to try it. I am with you Gerry on the waiting part. Curcumin is a constituent of turmeric and has been used safely for eons.

https://www.michaeljfox.org/foundati...in-phase-trial

Debi

Hello from France,
Any news from this Prothena study?
Thanks.

http://neurotalk.psychcentral.com/thread217683.html

Yes, the Phase 1 results reported were great. Dramatic reduction in free serum alpha-synuclein along with a very good safety profile (well tolerated) with just one dose. Of course, we still need to see if a reduction in a-syn will actually lead to a slowing, stopping or reversal of the disease. That won't be known until they report some interim results from the ongoing phase 2 study.

http://ir.prothena.com/releasedetail...leaseID=902569